PTGFR

Across TCGA pan-cancer cohorts, PTGFR Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PTGFR data layer compared with 24 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher PTGFR Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated PTGFR expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

BRCA, BLCA, and COAD are the cancer types where PTGFR Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Median	All	0.103	0.578	.002	24	view →
BLCA	OS	Median	All	0.141	0.687	.003	21	view →
COAD	OS	Median	All	0.464	0.873	<.001	18	view →
SCLC	OS	Median	IV	0.137	0.548	.004	12	view →
LIHC	DFS	Median	All	0.117	0.557	<.001	12	view →
SKCM	DFS	Median	IV	1.000	0.201	.047	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PTGFR–BRCA (OS)

Open the BRCA breakdown →